Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7061-7068

  Hong, David S ^a   Sebti, Said M ^b,c   Newman, Robert A ^a   Blaskovich, Michelle A ^b,c   Ye, Lei ^a   Gagel, Robert F ^a   Moulder, Stacy ^a   Wheler, Jennifer J ^a   Naing, Aung ^a   Tannir, Nizar M ^a   Ng, Chaan S ^a   Sherman, Steven I ^a   El Naggar, Adel K ^a   Khan, Rabia ^a   Trent, Jon ^a   Wright, John J ^d   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYL TRANS TRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR; TIPIFARNIB;

ADULT; ADVANCED CANCER; AGED; ANAPLASTIC CARCINOMA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER REGRESSION; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; FEMALE; FOOT DISEASE; GENE MUTATION; HAND DISEASE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CARCINOMA; LETHARGY; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THYMOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; QUINOLONES; TREATMENT OUTCOME;

EID: 72549092909     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1241     Document Type: Article

References (30)

1. Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 2005;7: 297-300.
2. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-225 (Pubitemid 32947644)
3. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512 (Pubitemid 46630627)
4. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009;14:95-100.
5. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005;4:77-84.
6. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103:3271-3277
7. Johnston SR, Semiglazov VF, Manikhas GM, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110:327-335
8. Mesa RA, Camoriano JK, Geyer SM, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007;21:1964-1970
9. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004;22:1287-1292 (Pubitemid 41079843)
10. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinicallaboratory correlative trial. Blood 2001;97:3361-3369
11. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist 2005;10:565-578
12. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 2003; 17:123-129 (Pubitemid 36876672)
13. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-528
14. Kurzrock R, Kantarjian HM, Blascovich MA, et al. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res 2008;14:509-514
15. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003; 102:4527-4534 (Pubitemid 37494120)
16. McAuliffe JC, Trent JC. Biomarkers in gastrointestinal stromal tumor: should we equate blood-based pharmacodynamics with tumor biology and clinical outcomes? Clin Cancer Res 2007;13:2535-2536
17. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-1861 (Pubitemid 40826133)
18. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20:2726-2735 (Pubitemid 34575646)
19. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-941
20. Hong D, Ye L, Gagel R, et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008;7: 1001-1006
21. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134 (Pubitemid 46089673)
22. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22:3950-3957 (Pubitemid 41079877)
23. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science (New York) 2008;321:263-266
24. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-918 (Pubitemid 41103603)
25. Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008;144:779-782
26. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine- kinase inhibitor. Clin Exp Dermatol 2006; 31:783-785 (Pubitemid 44563396)
27. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719
28. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684
29. Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 2008; 8:625-632
30. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract 2008;5:737-740